More about our cookie policy.
Astrazeneca plc is the first company to sign an agreement with the European Commission for the COVID-19 vaccine.
The company agreed to supply the commission with up to 400 million doses of AZD-1222, which produces a surface protein that activates the immune formula to attack the SARS-CoV-2 virus if it infects a body. The first delivery is expected until the end of 2020.
The agreement provides all optional EU members with a non-profit vaccine. These members can also redirect dosages to other European countries.
Other corporations that are lately in talks with the commission to supply vaccines are Sanofi SA-Glaxosmithkline plc for three hundred million doses, Pfizer Inc., Moderna Inc., Johnson and Johnson, Biontech SE and Curevac BV.
Last July, Astrazeneca published provisional knowledge of AZD-1222’s blind, multicenter, randomized and controlled phase I/II clinical trial in 1,077 healthy adults who appeared to have tolerated the vaccine and had generated a physically powerful immune reaction opposed to the virus. Data showed a quadruple buildup of antibodies targeted against the complex protein of the virus in 95% of patients one month after injection. A T-cell reaction, culminating on day 14, was also induced and maintained for two months thereafter.
The vaccine is being studied lately in Phase II/III in the UK, Brazil and South America, and is expected to be aware by the end of 2020. Studies will begin in the United States this year.
In mid-June, Astrazeneca agreed to supply up to 400 million doses of vaccine to the European Alliance for Inclusive Vaccines, which includes Germany, France, Italy and the Netherlands.
Astrazeneca receives a significant amount of $1.2 billion from the U.S. government through Operation Warp Speed to produce three hundred million doses of AXD-1222, which is being developed through oxford University in the UK and authorized to Astrazeneca.
Novavax Vaccine Agreement in the UK
Novavax Inc. said it signed an agreement to supply the UK government with 60 million doses of NVX-CoV2373, its vaccine designed from the SARS-CoV-2 genetic series, in the first quarter of 2021. The agreement also includes a Phase III assessing the effectiveness of the vaccine in the British population.
Fujifilm Diosynth Biotechnologies will manufacture antigens in the UK, North Carolina and Texas. The UK is expected to produce 180 million doses a year.
The agreement with Novavax, in Gaithersburg, Maryland, follows the vaccine agreements already concluded with Astrazeneca, Valneva SE, Wockhardt Ltd., Sanofi and Glaxosmithkline.
Novavax’s agreement caused the company’s inventory (NASDAG: NVAX) to increase by 9.9% on August 14, with final inventories at $146.51. The last 12 months have seen a dramatic increase in Novavax inventories. On August 14, 2019, inventories charged just $6.04 and peaked at $178.51 on August 10.
The stocks faltered from August 10-12. JP Morgan analyst Eric Joseph wrote that reaction to Russia’s approval of a vaccine would possibly have played a role, as well as an Operation Warp Speed value for the positive incremental knowledge of Modern and Biontech Phase I on BNT -162b1, which possibly also would have contributed to weakness. Joseph wrote that “we would be buyers in recent weakness, maintaining our view that NVX-CoV2373 has the most productive benefit/risk profile of its kind” prior to the phase III progression.
Like Moderna and Astrazeneca, Novavax also signed an Operation Warp Speed agreement in the United States. On July 7, he signed up to supply a hundred million doses for $1.6 billion.
Preclinical knowledge showed that NVX-CoV2373 demonstrated an indication of antibodies to block the link of complex protein to receptors that target through the virus.
Novavax has its PHASE I/II test of NVX-CoV2373 in Australia. Phase III, a randomized, double-blind, placebo-controlled phase of 9,000 adults, is expected to begin in the third trimester of 2020. The clinical trial is designed to compare the responses of antibodies and T cells.
Enjoy a long-term policy to get the most comprehensive view of the market with BioWorld, BioWorld MedTech and BioWorld Asia in an easily accessible subscription.